Cough and Shortness of Breath with Losartan/HCTZ
Cough is NOT a significant side effect of losartan or hydrochlorothiazide—the incidence with losartan (17-29%) is similar to placebo (25-35%) and dramatically lower than ACE inhibitors (62-72%). 1, 2
Cough Profile
Losartan
The FDA label and clinical guidelines clearly establish that losartan does not cause the persistent dry cough characteristic of ACE inhibitors 2. In controlled trials specifically designed to test this:
- Losartan cough rate: 17-29%
- Placebo cough rate: 25-35%
- HCTZ cough rate: 25%
- ACE inhibitor (lisinopril) cough rate: 62-72%
These studies were conducted in patients who had confirmed ACE inhibitor-induced cough, and losartan performed no differently than placebo or HCTZ 2, 3. The ACCP guidelines (2006) explicitly state that losartan has a "low incidence of cough, similar to that of the diuretic hydrochlorothiazide" 1.
Important caveat: While rare case reports exist of losartan-induced cough 4, these are exceptional. In the large prescription-event monitoring study, 91% of patients who discontinued losartan due to cough had previously taken an ACE inhibitor, and 86% had prior ACE inhibitor cough—this represents carry-over effect, not true losartan-induced cough 5.
Hydrochlorothiazide
HCTZ does not cause cough as a medication side effect. The cough rate with HCTZ (25%) is indistinguishable from placebo 2.
Shortness of Breath (Dyspnea)
Losartan
Dyspnea is listed as a less common adverse reaction in the FDA label under "Respiratory, Thoracic and Mediastinal Disorders" 2. However, the incidence is not significantly different from placebo in controlled trials. In over 3,300 patients treated with losartan, dyspnea was not among the adverse events occurring in ≥2% of patients more commonly than placebo 2.
Hydrochlorothiazide
This is the critical concern. HCTZ can cause noncardiogenic pulmonary edema—a rare but potentially life-threatening reaction that presents with acute shortness of breath 6. Key features:
- Symptoms develop 10-150 minutes after ingestion
- Can occur on first exposure or with intermittent use
- 90% of cases occur in women
- Presents with sudden dyspnea, hypotension, and can progress to acute respiratory failure
- Often occurs in patients with a history of prior (milder) thiazide reaction
Clinical Algorithm
If a patient on losartan/HCTZ develops cough:
- First, investigate other causes (upper respiratory infection, postnasal drip, GERD, asthma)
- Review medication history—was the patient previously on an ACE inhibitor? If yes, this is likely carry-over cough that will resolve with time
- If truly new-onset persistent dry cough without other explanation, consider discontinuing and observing for 1-4 weeks (up to 3 months in some cases) 1
- The cough is unlikely to be from losartan or HCTZ based on the evidence
If a patient on losartan/HCTZ develops shortness of breath:
- Immediately assess for acute pulmonary edema (HCTZ-induced noncardiogenic pulmonary edema)
- Timing: Did symptoms start within minutes to hours of taking the medication?
- Severity: Acute onset, hypotension, respiratory distress?
- History: Any prior reaction to thiazides?
- If acute presentation with temporal relationship to HCTZ, discontinue immediately and manage as acute pulmonary edema
- If gradual onset, evaluate for heart failure, pulmonary disease, anemia, or other causes
- HCTZ-induced pulmonary edema requires permanent discontinuation of all thiazide diuretics
Safety Profile
The losartan/HCTZ combination demonstrates excellent tolerability across age groups, including very elderly patients (≥75 years) 7. In large real-world studies, adverse effects were rare, and the combination was safe and effective 8. Discontinuation rates due to adverse events with losartan (2.3%) were actually lower than placebo (3.7%) 2, 9.